CABINET Trial: Study Design and Patient Population
A panelist discusses how the CABINET trial was a National Cancer Institute (NCI)–supported study conducted by the Alliance for Clinical Trials in Oncology that enrolled patients with well-differentiated grade 1 through 3 pancreatic or extrapancreatic neuroendocrine tumors who had progressed after somatostatin analogue therapy and at least 1 other FDA-approved therapy.
Video content above is prompted by the following:
The CABINET Trial Design and Significance
Key Themes:
- Trial Design:
- NCI-supported study run through the Alliance for Clinical Trials in Oncology network
- Included well-differentiated grade 1, 2, or 3 pancreatic or extrapancreatic neuroendocrine tumors
- Required disease progression after somatostatin analogue therapy and at least 1 other FDA-approved therapy
- 2:1 randomization to cabozantinib vs placebo with crossover option
- Trial Significance:
- Rigorously conducted through academic institutions and large community practices
- Particularly important for demonstrating active therapy post radioligand therapy
- Protocol modifications improved accrual rates as the trial progressed
Notable Insights:
Dr Halfdanarson emphasized that the CABINET trial provides valuable evidence for treatment options following radioligand therapy with lutetium-177 dotatate, addressing a knowledge gap in the field.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
